For nearly a decade, the Supreme Court’s FTC v. Actavis decision has guided pharmaceutical litigators and advisors exploring the antitrust risks inherent in settling pharmaceutical patent lawsuits, especially when such...more
3/3/2022
/ Anti-Competitive ,
Biosimilars ,
Dormant Commerce Clause ,
Federal Trade Commission (FTC) ,
FTC v Actavis ,
Hatch-Waxman ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Reverse Payment Settlement Agreements
Biologics are revolutionizing the pharmaceutical industry, and in doing so, garnering an increasing share of antitrust attention. In recent years, the FTC, FDA, and antitrust plaintiffs’ bar have raised concerns about a...more
A federal district court recently dismissed a lawsuit against AbbVie and biosimilar manufacturers of adalimumab involving a novel antitrust claim against the Humira patent estate. Attorneys with Haug Partners LLP take an...more
7/20/2020
/ AbbVie ,
Amgen ,
Anticompetitive Behavior ,
Antitrust Litigation ,
Antitrust Violations ,
Biosimilars ,
BPCIA ,
Defense Strategies ,
Dismissals ,
Drug Pricing ,
EU ,
Federal Trade Commission (FTC) ,
Foreign Patent Applications ,
Indirect Purchasers ,
Litigation Strategies ,
Noerr-Pennington Doctrine ,
Orange Book ,
Patent Dance ,
Patent Portfolios ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Popular ,
Product Exclusivity